Cellmyx, operating under the name Millennium Medical Technologies, has received medical device licence (MDL) approval from Health Canada for its intelliFatBOD technology.
The technology, which is also approved in the US, is intended for use in a range of surgical procedures.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
They include orthopaedic, arthroscopic, thoracic, laparoscopic, plastic, cosmetic and reconstructive surgeries.
By using the patient’s own adipose tissue, the technology aids in the patient’s recovery and healing.
It is in line with the latest guidelines of both the US Food and Drug Administration (FDA) and Health Canada, helping to maintain the cellular and tissue microarchitecture of adipose tissue, removing residual oil emulsion and blood.
The intelliFatBOD technology also follows minimally manipulated standards for Human Cell and Tissue Products.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe technology is expected to potentially bring about a significant transformation in the areas of orthopaedic, plastic and cosmetic surgery.
Cellmyx founder and CEO Greg Miles said: “We are thrilled to have received Health Canada MDL clearance for intelliFatBOD. This technology marks a significant leap forward in medical solutions, allowing physicians to harness the body’s natural resources to enhance patient outcomes.
“We are committed to advancing the art of cosmetic surgery and regenerative medicine and intelliFatBOD is a prime example of our dedication to that mission.”
Cellmyx provides comprehensive solutions for the harvesting, isolation and deployment of PHSA 361-compliant tissue and cells.
